177 related articles for article (PubMed ID: 22661920)
1. Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.
Zanuy M; Ramos-Montoya A; Villacañas O; Canela N; Miranda A; Aguilar E; Agell N; Bachs O; Rubio-Martinez J; Pujol MD; Lee WN; Marin S; Cascante M
Metabolomics; 2012 Jun; 8(3):454-464. PubMed ID: 22661920
[TBL] [Abstract][Full Text] [Related]
2. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.
Fry DW; Bedford DC; Harvey PH; Fritsch A; Keller PR; Wu Z; Dobrusin E; Leopold WR; Fattaey A; Garrett MD
J Biol Chem; 2001 May; 276(20):16617-23. PubMed ID: 11278443
[TBL] [Abstract][Full Text] [Related]
4. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
6. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
[TBL] [Abstract][Full Text] [Related]
7. Mice thrive without Cdk4 and Cdk2.
Barrière C; Santamaría D; Cerqueira A; Galán J; Martín A; Ortega S; Malumbres M; Dubus P; Barbacid M
Mol Oncol; 2007 Jun; 1(1):72-83. PubMed ID: 19383288
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A.
Fåhraeus R; Paramio JM; Ball KL; Laín S; Lane DP
Curr Biol; 1996 Jan; 6(1):84-91. PubMed ID: 8805225
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G1 regulatory proteins: p27Kip1 up-regulation is a relevant early event.
Zancai P; Cariati R; Rizzo S; Boiocchi M; Dolcetti R
Oncogene; 1998 Oct; 17(14):1827-36. PubMed ID: 9778049
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
[TBL] [Abstract][Full Text] [Related]
11. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression.
Keenan SM; Lents NH; Baldassare JJ
J Biol Chem; 2004 Feb; 279(7):5387-96. PubMed ID: 14645251
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Lukas C; Jensen SK; Bartkova J; Lukas J; Bartek J
Hybridoma; 1999 Jun; 18(3):225-34. PubMed ID: 10475236
[TBL] [Abstract][Full Text] [Related]
14. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
15. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.
Malumbres M; Sotillo R; Santamaría D; Galán J; Cerezo A; Ortega S; Dubus P; Barbacid M
Cell; 2004 Aug; 118(4):493-504. PubMed ID: 15315761
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma.
Easton J; Wei T; Lahti JM; Kidd VJ
Cancer Res; 1998 Jun; 58(12):2624-32. PubMed ID: 9635589
[TBL] [Abstract][Full Text] [Related]
17. Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4.
Warenius HM; Kilburn JD; Essex JW; Maurer RI; Blaydes JP; Agarwala U; Seabra LA
Mol Cancer; 2011 Jun; 10():72. PubMed ID: 21668989
[TBL] [Abstract][Full Text] [Related]
18. Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation.
Franklin DS; Xiong Y
Mol Biol Cell; 1996 Oct; 7(10):1587-99. PubMed ID: 8898364
[TBL] [Abstract][Full Text] [Related]
19. Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice.
Tong W; Pollard JW
Mol Cell Biol; 1999 Mar; 19(3):2251-64. PubMed ID: 10022912
[TBL] [Abstract][Full Text] [Related]
20. The interplay of CDK4 and CDK6 in melanoma.
Kollmann K; Briand C; Bellutti F; Schicher N; Blunder S; Zojer M; Hoeller C
Oncotarget; 2019 Feb; 10(14):1346-1359. PubMed ID: 30858922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
